We are excited to introduce our new report for the Lipoprotein Particle Profile™. We believe the changes that have been made will make the report easier to read and will facilitate your assessment of risk and the selection of patient specific treatment programs.
Addition of the Traditional Lipid Panel (Cholesterol, Triglycerides, HDL, LDL)
Many physicians continue to utilize the traditional cholesterol or lipid panel for guidance in the selection of an appropriate treatment strategy. Although we believe that the treatment is better determined by the application of the results from HDL and LDL subgroups and their particle numbers, the traditional lipid panel continues to be used for risk assessment and we are therefore including it in our report.
Elimination of CEQ
Many physicians and their patients found the practice of reporting lipoprotein test results in terms of cholesterol equivalents confusing. Therefore, we are eliminating this concept from our report.
Addition of ApoB, non-HDL cholesterol and non-HDL particle numbers
A value for non-HDL cholesterol has been included since it is likely to be the new NCEP ATP IV target of therapy when the guidelines are released later this year. Additionally we have added Apolipoprotein B and non-HDL particle numbers which were the focus of the Consensus Statement of the American College of Cardiology and the American Diabetes Association for better risk assessment. Individual variability in the triglyceride and cholesterol composition of the lipoprotein subgroups can make particle numbers more meaningful in risk assessment.
tOther report changes include:
• Lp(a) results have been moved to the Risk Modification section.
• The reporting units for hs-CRP have been changed from mg/dL to mg/L which changes the reference range to 0.00 – 3.00 mg/L.
• The LDL mean size/phenotype result has been deleted as this result can often be misleading as a result of variances in the total LDL result.
• The Apo B reference range has been changed to 40 – 100 mg/dL.
• The Apo A1 reference range has been changed to 115 – 224 mg/dL. This test is not a part of the LPP™ Basic or Plus panels, it must be ordered separately.
Are you using a cardiovascular risk assessment in your practice?
